Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Apertura Gene Therapy
AddedFeb 17, 2024
UpdatedJun 18, 2026
Apertura Gene Therapy

Apertura Gene Therapy

Series A

Apertura Gene Therapy: A biotech firm pioneering gene therapy for debilitating diseases.

HQ
New York City, NY, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Apertura Gene Therapy is a biotechnology company focused on pioneering next-generation AAV gene therapies through innovative capsid and payload engineering. The company's core mission is to open new opportunities for treating debilitating diseases with limited patient options. Apertura designs AAV capsids, regulatory elements, and payloads to overcome existing limitations in gene delivery and expression, aiming to bring the future of gene therapy into focus.

Apertura Gene Therapy has assembled a world-class team of experts in vector engineering, gene regulation, machine learning, and the treatment of rare diseases. This collaborative effort has enabled the company to build a robust pipeline of advanced gene therapies. Their innovative approach and cutting-edge technology have positioned them as leaders in the field, making significant strides in addressing unmet medical needs.

Apertura Gene Therapy - Similar Companies

Aavogen logo

Aavogen

aavogen.com

Agtc logo

Agtc

beacontx.com

Jaguar Gene Therapy logo

Jaguar Gene Therapy

Dyno Therapeutics logo

Dyno Therapeutics

dynotx.com

Exegenesis Bio logo

Exegenesis Bio

exegenesisbio.com

Capsida Biotherapeutics logo

Capsida Biotherapeutics

capsida.com

Kate Therapeutics logo

Kate Therapeutics

Apic Bio logo

Apic Bio

Code Biotherapeutics logo

Code Biotherapeutics

codebiotx.com

Bedrock Therapeutics logo

Bedrock Therapeutics

Frontera Therapeutics logo

Frontera Therapeutics

Chameleon Biosciences logo

Chameleon Biosciences

Affinia Therapeutics logo

Affinia Therapeutics

affiniatx.com

Lacerta Therapeutics logo

Lacerta Therapeutics

Intergalactic Therapeutics logo

Intergalactic Therapeutics

Apertura Gene Therapy - Quick Facts

Who are Apertura Gene Therapy's competitors?

Companies similar to Apertura Gene Therapy include Aavogen, Agtc, Jaguar Gene Therapy and Dyno Therapeutics.

When was Apertura Gene Therapy founded?

Apertura Gene Therapy was founded in 2021.

Where is Apertura Gene Therapy's headquarters located?

Apertura Gene Therapy's headquarters is located in New York City, NY, US.

When was Apertura Gene Therapy's last funding round?

Apertura Gene Therapy's most recent funding round was for $67M (USD) in April 2022.

How much has Apertura Gene Therapy raised to-date?

As of Apr 26, 2022, Apertura Gene Therapy has raised a total of $67M (USD).

How many employees does Apertura Gene Therapy have?

Apertura Gene Therapy has 29 employees as of Feb 4, 2024.

Apertura Gene Therapy - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Gene Therapy
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified